Joanna Bidzinska

Dr. Joanna Bidzinska

2nd Department of Radiology, Medical University of Gdansk, Gdansk, Poland
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2013 in Molecules
Verified
Journal Article
Open access
PDF file
JBJoanna Bidzinska
Joanna Bidzinska
GCGraziella Cimino-Reale
Graziella Cimino-Reale
Nadia ZaffaroniNadia Zaffaroni
Nadia Zaffaroni
Marco FoliniMarco Folini
Marco Folini
G-quadruplexes are secondary structures that may form within guanine-rich nucleic acid sequences. Telomeres have received much attention in this regard since they can fold into several distinct intramolecular G-quadruplexes, leading to the rational design and development of G-quadruplex‑stabilizing molecules. These ligands were shown to selectively exert an antiproliferative and chemosensitizing activity in in vitro and in vivo tumor models, without appreciably affecting normal cells. Such findings point to them as possible drug candidates for clinical applications. Other than in telomeres, G-quadruplexes may form at additional locations in the human genome, including gene promoters and untranslated regions. For instance, stabilization of G-quadruplex structures within the promoter of MYC, KIT, or KRAS resulted in the down-regulation of the corresponding oncogene either in gene reporter assays or in selected experimental models. In addition, the alternative splicing of a number of genes may be affected for a therapeutic benefit through the stabilization of G-quadruplexes located within pre-mRNAs. It is now emerging that G-quadruplex structures may act as key regulators of several biological processes. Consequently, they are considered as attractive targets for broad-spectrum anticancer therapies, and much effort is being made to develop a variety of ligands with improved G-quadruplex recognition properties. Quarfloxin, a fluoroquinolone derivative designed to target a G-quadruplex within ribosomal DNA and disrupt protein-DNA interactions, has entered clinical trials for different malignancies. This review will provide some hints on the role of G-quadruplex structures in biological processes and will evaluate their implications as novel therapeutic targets.

11 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MRMarta Recagni
Marta Recagni
JBJoanna Bidzinska
Joanna Bidzinska
Nadia ZaffaroniNadia Zaffaroni
Nadia Zaffaroni
Marco FoliniMarco Folini
Marco Folini
Telomere maintenance mechanisms (i.e., telomerase activity (TA) and the alternative lengthening of telomere (ALT) mechanism) contribute to tumorigenesis by providing unlimited proliferative capacity to cancer cells. Although the role of either telomere maintenance mechanisms seems to be equivalent in providing a limitless proliferative ability to tumor cells, the contribution of TA and ALT to the clinical outcome of patients may differ prominently. In addition, several strategies have been developed to interfere with TA in cancer, including Imetelstat that has been the first telomerase inhibitor tested in clinical trials. Conversely, the limited information available on the molecular underpinnings of ALT has hindered thus far the development of genuine ALT-targeting agents. Moreover, whether anti-telomerase therapies may be hampered or not by possible adaptive responses is still debatable. Nonetheless, it is plausible hypothesizing that treatment with telomerase inhibitors may exert selective pressure for the emergence of cancer cells that become resistant to treatment by activating the ALT mechanism. This notion, together with the evidence that both telomere maintenance mechanisms may coexist within the same tumor and may distinctly impinge on patients’ outcomes, suggests that ALT may exert an unexpected role in tumor biology that still needs to be fully elucidated.

19 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JBJoanna Bidzinska
Joanna Bidzinska
Edyta SzurowskaEdyta Szurowska
Edyta Szurowska
A lot has happened in the field of lung cancer screening in recent months. The ongoing discussion and documentation published by the scientific community and policymakers are of great importance to the entire European community and perhaps beyond. Lung cancer is the main worldwide killer. Low-dose computed tomography-based screening, together with smoking cessation, is the only tool to fight lung cancer, as it has already been proven in the United States of America but also European randomized controlled trials. Screening requires a lot of well-organized specialized work, but it can be supported by artificial intelligence (AI). Here we discuss whether and how to use AI for patients, radiologists, pulmonologists, thoracic surgeons, and all hospital staff supporting screening process benefits.

1 July 2008 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
MWMaciej Woźny
Maciej Woźny
PBPawel Brzuzan
Pawel Brzuzan
MŁMichał K. Łuczyński
Michał K. Łuczyński
MGMaciej Góra
Maciej Góra
JBJoanna Bidzinska
Joanna Bidzinska
PJPaweł Jurkiewicz
Paweł Jurkiewicz

1 August 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JBJoanna Bidzinska
Joanna Bidzinska
LPLorenzo Di Pietro
Lorenzo Di Pietro
ENEISA NAGHSHINEH
EISA NAGHSHINEH
CPCecilia Pandini
Cecilia Pandini
FDFilippo Doria
Filippo Doria
Marco FoliniMarco Folini
Marco Folini
Telomeric G-quadruplexes (G4s) represent intriguing targets for tumours characterized by the Alternative Lengthening of Telomere (ALT) mechanism. Here we have investigated the effects of two naphthalene diimide (NDI)-based G4 interacting agents (NMe2 and QN-302) in a pair of ALT-positive human osteosarcoma (U-2 OS and Saos-2) cell lines. Both NDIs displayed marked cell growth inhibitory activity associated with the induction of telomere dysfunctions. Moreover, NDI-treated cells were characterized by perturbations at the mitochondrial level as suggested by an increase in the production of reactive oxygen species, the occurrence of changes in mitochondria density and morphology. However, upon initial inhibition of cell growth, U-2 OS cells withstood ligand-induced stress compared to Saos-2 cells. This ability was in part sustained, in a ligand-dependent manner, by the lack of ALT activity inhibition, as indicated by the levels of telomeric C-circle DNA and of Bloom helicase, a member of the RecQ family of helicases. Moreover, marked basal antioxidant capacity, together with the capability to mount an antioxidant response that is in part mediated by the nuclear factor erythroid 2-related factor, has endowed U-2 OS cells with the ability to adapt to NDI exposure. Our data indicate that NDIs rapidly affect the growth of ALT cancer cells by interfering with telomere and mitochondria homeostasis and suggest that small molecule-mediated stabilization of G4s may be a promising therapeutic strategy in ALT-positive tumors. Nonetheless, depending on the individual NDI and the cell’s genetic background, cellular adjustment mechanisms may become activated. This, in turn may impinge on the biological activity of G4 interacting agents. Deciphering these mechanisms and the associated molecular determinants will help accelerating the development of G4-based therapeutic interventions in ALT tumors.

31 March 2014 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
JBJoanna Bidzinska
Joanna Bidzinska
MBMaciej Baginski
Maciej Baginski
ASAndrzej Skladanowski
Andrzej Skladanowski
The ends of chromosomes in mammals are composed of telomeric DNA containing TTAGGG repeats, which bind specific proteins called shelterins. This telomeric DNA together with shelterins form a cap that protects the ends of chromosomes from being recognized as sites of DNA damage and from chromosomal fusions. Many very successful antitumor drugs used in the treatment of cancer patients bind to DNA, some of them with a prominent sequence specificity leads to changes in DNA structure and integrity. We propose a new target for antitumor drugs where small molecule ligands can bind to telomeric DNA and induce specific structural changes. These changes would lead to a selective interference with the formation of telomeric DNA-shelterin complexes, especially involving TRF1 and TRF2 proteins, as these proteins bind double-stranded telomeric DNA in a sequence- and structure-dependent manner. The rationale of the proposed therapeutic strategy is further justified by the fact that tumor cells have relatively short telomeres and frequently de-regulated shelterin expression and/or functionality. Thus uncapping of chromosome ends by DNA binding compounds which disrupt DNA-shelterin complexes can ultimately induce selective cytotoxic effect in tumor cells. Possible implications for rational design of new antitumor drugs which interfere with telomeric DNA structure and formation of DNA-shelterin complexes are discussed.